Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Common Equity of -$46.0 million for Q1 2026, up 65.18% year-over-year from -$27.8 million in Q1 2025, and up 35.55% quarter-over-quarter from -$71.3 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at -$46.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 65.18% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$46.0 million (up 65.18% YoY), while the FY2025 annual figure was -$71.3 million, up 34.87% from the prior year.
- Common Equity for Q1 2026 stood at -$46.0 million, up from -$71.3 million in the prior quarter.
- The five-year high for Common Equity was $407.4 million in Q1 2022, with the low at -$132.0 million in Q1 2025.
- The 5-year median for Common Equity is -$46.0 million (2026), against an average of $36.6 million.
- The sharpest annual moves came in 2024 and 2026: Common Equity slumped 647.26% in 2024, then surged 65.18% in 2026.
- Amneal Pharmaceuticals' Common Equity stood at $184.0 million in 2022, then plunged by 89.12% to $20.0 million in 2023, then plunged by 647.26% to -$109.5 million in 2024, then soared by 34.87% to -$71.3 million in 2025, then surged by 35.55% to -$46.0 million in 2026.
- Business Quant data shows AMRX's Common Equity at -$46.0 million in Q1 2026, -$71.3 million in Q4 2025, and -$109.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 33.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.02 Mn |
| Mar 31, 2026 | -45.97 Mn |
| Dec 31, 2025 | -71.33 Mn |
| Sep 30, 2025 | -109.46 Mn |
| Jun 30, 2025 | -112.53 Mn |
| Mar 31, 2025 | -132.00 Mn |
| Dec 31, 2024 | -109.51 Mn |
| Sep 30, 2024 | -93.57 Mn |
| Jun 30, 2024 | -57.49 Mn |
| Mar 31, 2024 | -63.63 Mn |
| Dec 31, 2023 | 20.01 Mn |
| Sep 30, 2023 | 154.24 Mn |
| Jun 30, 2023 | 150.77 Mn |
| Mar 31, 2023 | 134.67 Mn |
| Dec 31, 2022 | 183.98 Mn |
| Sep 30, 2022 | 194.29 Mn |
| Jun 30, 2022 | 172.99 Mn |
| Mar 31, 2022 | 407.41 Mn |
| Dec 31, 2021 | 366.97 Mn |
| Sep 30, 2021 | 383.17 Mn |